Apheresis in the pediatric patient
β Scribed by Christina A. Kasprisin; Duke O. Kasprisin
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 231 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
As therapeutic apheresis becomes more and more popular, its use in children has remained limited. in most cases, the reports that do exist are either brief abstracts or a notation in a larger group of adult patients.
π SIMILAR VOLUMES
The practice of transfusing ABO-incompatible platelets, driven primarily by concerns about inventory management, has been considered generally safe because the accompanying plasma is usually diluted in the recipient's total blood volume. However, if the platelet product contains a large volume of pl
Therapeutic apheresis in pediatrics requires selected modifications due to the child's smaller size, blood volume, and developmental age. Red blood cell priming is used to prevent dilution of the child's hematocrit from the normal saline prime. Continuous flow cell separators maintain isovolemia. Di
## Abstract __Background.__ The mortality rate of children with tracheotomies is estimated to be between 11% and 40%, although the incidence of tracheotomyβrelated deaths is only between 0% and 3.4%. The purpose of this report was to analyze the mortality rate in children with tracheotomies. __Met
## Abstract Therapeutic apheresis procedures in critically ill patients comprises of therapeutic plasma exchange in most cases but also less commonly, erythrocytapheresis (red cell exchange), thrombocytapheresis, or leukocytapheresis. These procedures present a number of challenges to the apheresis
Coronary artery disease is a common problem in the adult population. However, it is rather a rare event in children. The most common cause of acquired coronary artery disease in children is Kawasaki disease. Some patients with coronary arterial stenoses after Kawasaki disease have been amenable for